NCT03189836View on ClinicalTrials.gov

Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 4, 2017

Primary Completion Date

September 21, 2020

Study Completion Date

September 21, 2020

Conditions
Lymphoma
Interventions
BIOLOGICAL

ACTR707

autologous T cell product

BIOLOGICAL

rituximab

CD20-directed cytolytic antibody

Trial Locations (11)

21201

University of Maryland, Baltimore

30322

Emory University, Winship Cancer Institute, Atlanta

37203

Tennessee Oncology - Nashville, Nashville

43210

Ohio State University, Columbus

46327

Indiana Bone and Marrow Transplantation, Indianapolis

53226

Medical College of Wisconsin, Milwaukee

55455

University of Minnesota, Minneapolis

60153

Loyola University, Maywood

77030

The University of Texas MD Anderson Cancer Center, Houston

85234

Banner MD Anderson Cancer Center, Gilbert

06520

Yale University, New Haven

Sponsors
All Listed Sponsors
lead

Cogent Biosciences, Inc.

INDUSTRY

NCT03189836 - Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma | Biotech Hunter | Biotech Hunter